ADT-OH

CAT: 0804-HY-109582-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-109582-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases[1][5].
CAS Number
[18274-81-2]
Product Name Alternative
5- (4-Hydroxyphenyl) -3H-1,2-dithiole-3-thione; ACS 1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; FAK
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/adt-oh.html
Concentration
10mM
Purity
98.55
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
S=C1SSC(C2=CC=C(O)C=C2)=C1
Molecular Formula
C9H6OS3
Molecular Weight
226.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Cai F, et al. ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. Cell Death Dis. 2020;11 (1) :33.|[2]Yu S, et al. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission. Cell Death Dis. 2024 Jun 28;15 (6) :463. |[3]Xu H, et al. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. Cancer Med. 2023 Aug;12 (16) :17193-17211.|[4]Wei SW, et al. Role of the hydrogen sulfide-releasing donor ADT-OH in the regulation of mammal neural precursor cells. J Cell Physiol. 2022 Jul;237 (7) :2877-2887.|[5]Li CY, et al. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways. Eur J Pharmacol. 2019 Dec 1;864:172719.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-177106-01ADT-1004
HY-157887-01ADT-007
HY-145779H-Glu (Met-OH) -OH
HY-174087Thalidomide-4-OH-C11-OH
HY-145779A-01H-Glu (Met-OH) -OH (TFA)
HY-W010770-01Fmoc-Thr[PO (OBzl) OH]-OH
HY-132977-01BTTAA-OH
HY-133144-01Lenalidomide-OH
HY-168803-01BDW-OH
HY-150970ICy-OH

Alternative Products

CatalogName
MBS3846874-01ADT-OH
A22351-200ADT-OH 200mg
A22351-50ADT-OH 50mg
A22351-100ADT-OH 100mg
A22351-5ADT-OH 5mg
A22351-10ADT-OH 10mg
A22351-25ADT-OH 25mg
A22351-10mM-DADT-OH 10mM * 1mL in DMSO
JH918234ADT-007
T210541-01ADT-1004

Popular Products